We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
divider
If you are interested in participating in a clinical trial, you have the following options:
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
View Trial DetailsA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Bristol Myers Squibb is united by our mission to transform patient’s lives through science by discovering, developing, and delivering innovative medicines that help prevail over serious diseases.To that end, we are committed to doing our part to help ensure patients have a fair and just opportunity to achieve optimal health outcomes.
We are working to improve the recruitment of diverse patients with the goal that the clinical trial population becomes more reflective of the real-world population and the people impacted by the diseases studied.
divider
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information